For example, bevacizumab and recombinant human endostatin combined with cytotoxic drugs are commonly administered in advanced NSCLC. Aflibercept has been approved for the second-line treatment of advanced colorectal cancer. This evidence concerns the gene COL18A1 and non-small cell lung carcinoma.